← Back to Treatments
🏅 FDA Orphan Designation

Bexxar

Tositumomab and iodine I 131 tositumomab

Manufacturer: GlaxoSmithKline LLC

Indicated for:
T-cell non-Hodgkin lymphomaOrphanComposite lymphoma

FDA-Approved Indications (2)

T-cell non-Hodgkin lymphomaOrphan Designation

Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy

Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy

Population: adults

Indications & Usage

Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy

💙 Support Programs

View all →
Bexxar
GlaxoSmithKline LLC

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.